K Morarji1, O McArdle1, K Hui1, G Gingras-Hill1, S Ahmed1, E M Greenblatt2,3, E Warner4, S Sridhar5, A M F Ali4, A Azad6, D C Hodgson1. 1. Department of Radiation Oncology, Princess Margaret Hospital. 2. Department of Obstetrics and Gynecology, Mount Sinai Hospital. 3. University of Toronto. 4. Department of Medical Oncology, Odette Cancer Centre. 5. Department of Medical Oncology, Princess Margaret Hospital; and. 6. Pathology and Laboratory Medicine Unit, Mount Sinai Hospital, Toronto, ON.
Abstract
BACKGROUND: As cure rates for breast cancer improve, there is increasing evidence that late effects of treatment-and impaired fertility in particular-are emerging as important concerns among young breast cancer survivors. Older reports have evaluated the occurrence of amenorrhea after treatment, but few data have been reported about the incidence of biochemical evidence for impaired ovarian function in patients who do not become overtly menopausal. METHODS: We conducted a cross-sectional study evaluating anti-Müllerian hormone (amh) in premenopausal chemotherapy-treated breast cancer survivors and control patients. Random serum levels of amh and other relevant clinical data were collected for 100 premenopausal chemotherapy-treated breast cancer survivors and 76 control subjects. Subgroup analyses were performed for women with regular menstrual cycles at the time of amh testing. RESULTS: After adjustment for age, amh was significantly lower in the overall group of patients receiving chemotherapy (p = 0.002) and in the subgroup reporting normal cycles (p = 0.03). Cyclophosphamide produced a significant dose-dependent reduction in amh (p < 0.001); trastuzumab was associated with increased amh in survivors with normal cycles. Overall, serum amh in survivors was roughly equivalent to that measured in control patients 12 years older. CONCLUSIONS: Young breast cancer survivors often experience significant impairment of ovarian function despite having normal menstrual cycles after treatment. Those results have important implications for patient counselling and the timing of possible referral to a fertility specialist.
BACKGROUND: As cure rates for breast cancer improve, there is increasing evidence that late effects of treatment-and impaired fertility in particular-are emerging as important concerns among young breast cancer survivors. Older reports have evaluated the occurrence of amenorrhea after treatment, but few data have been reported about the incidence of biochemical evidence for impaired ovarian function in patients who do not become overtly menopausal. METHODS: We conducted a cross-sectional study evaluating anti-Müllerian hormone (amh) in premenopausal chemotherapy-treated breast cancer survivors and control patients. Random serum levels of amh and other relevant clinical data were collected for 100 premenopausal chemotherapy-treated breast cancer survivors and 76 control subjects. Subgroup analyses were performed for women with regular menstrual cycles at the time of amh testing. RESULTS: After adjustment for age, amh was significantly lower in the overall group of patients receiving chemotherapy (p = 0.002) and in the subgroup reporting normal cycles (p = 0.03). Cyclophosphamide produced a significant dose-dependent reduction in amh (p < 0.001); trastuzumab was associated with increased amh in survivors with normal cycles. Overall, serum amh in survivors was roughly equivalent to that measured in control patients 12 years older. CONCLUSIONS: Young breast cancer survivors often experience significant impairment of ovarian function despite having normal menstrual cycles after treatment. Those results have important implications for patient counselling and the timing of possible referral to a fertility specialist.
Entities:
Keywords:
Anti-Müllerian hormone; breast cancer survivors; chemotherapy; ovarian reserve
Authors: M N Levine; V H Bramwell; K I Pritchard; B D Norris; L E Shepherd; H Abu-Zahra; B Findlay; D Warr; D Bowman; J Myles; A Arnold; T Vandenberg; R MacKenzie; J Robert; J Ottaway; M Burnell; C K Williams; D Tu Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: H Irene Su; Mary D Sammel; Jamie Green; Luke Velders; Corrie Stankiewicz; Jennifer Matro; Ellen W Freeman; Clarisa R Gracia; Angela DeMichele Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Sheila Krishnan Mody; Jessica R Gorman; Lisa P Oakley; Tracy Layton; Barbara A Parker; Danielle Panelli Journal: J Cancer Surviv Date: 2019-05-08 Impact factor: 4.442
Authors: Valentino Martelli; Maria Maddalena Latocca; Tommaso Ruelle; Marta Perachino; Luca Arecco; Kristi Beshiri; Maria Grazia Razeti; Marco Tagliamento; Maurizio Cosso; Piero Fregatti; Matteo Lambertini Journal: Breast Cancer (Dove Med Press) Date: 2021-05-24